SCHEMBL5485863

SCHEMBL5485863

CC(=O)Nc1ccc(C2(c3ccc(NC(C)=O)cc3)C(=O)Nc3c(C)cccc32)cc1

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTT P42858 2/20 0.67
CNR1 P21554 1/20 0.67
GPR35 Q9HC97 1/20 0.67
GPR55 Q9Y2T6 1/20 0.67
SMN1; SMN2 Q16637 4/20 0.66
TDP1 Q9NUW8 1/20 0.41
HSD17B10 Q99714 4/20 0.41
ALDH1A1 P00352 4/20 0.41
NPC1 O15118 3/20 0.41
RAB9A P51151 2/20 0.41
KDM4E B2RXH2 1/20 0.41
TP53 P04637 1/20 0.41
HPGD P15428 1/20 0.41
MAPT P10636 4/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
NAPRT Q6XQN6 1/20 0.39
TSHR P16473 2/20 0.39
KMT2A Q03164 4/20 0.39
POLB P06746 3/20 0.39
TAAR1 Q96RJ0 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5488536 0.81 SMN1; SMN2 (0.55) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL29443920 0.80 GPR55 (1.00) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5478375 0.80 GPR55 (1.00) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5478939 0.80 SMN1; SMN2 (0.56) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5482648 0.79 SMN1; SMN2 (0.62) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL5482300 0.78 SMN1; SMN2 (0.52) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL6048373 0.77 CNR1 (0.91) HTTCNR1GPR35GPR55SMN1; SMN2
SCHEMBL23973627 0.75 CNR1 (0.69) HTTCNR1GPR35GPR55HSD17B10
SCHEMBL5478145 0.75 SMN1; SMN2 (0.60) HTTSMN1; SMN2TDP1HSD17B10ALDH1A1
SCHEMBL23791613 0.75 GPR55 (0.86) HTTCNR1GPR35GPR55SMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US claimed
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer TOPO TARGET A/S (DK) 2007-12-27 US disclosed
EP-1734951-A2 DIPHENYL-INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TopoTarget A/S (DK) 2006-12-27 EP disclosed
WO-2005097107-A2 DIPHENYL - INDOL-2-ON COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER TOPOTARGET A/S (DK) 2005-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070299102-A1 Diphenyl Ox-Indol-2-One Compounds and Their Use in the Treatment of Cancer MTOR, RICTOR, CDK4 HTT 1880/4885CNR1 973/4885GPR35 2558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.